GSK's two-drug HIV Dovato treatment meets main goal in study

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.